| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
Published online before print November 30, 2007
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
-Synuclein-Related Pathogenic Changes in Neuronal Cells
,
From the Department of Cellular Biochemistry and Human Genetics,* Hebrew University, Hadassah Medical School, Jerusalem, Israel; and the Center for Neurologic Diseases,
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
@ To whom correspondence should be addressed. E-mail: rsharon{at}md.huji.ac.il.
| Abstract |
|---|
The misfolding and aggregation of normally soluble proteins has emerged as a key feature of several neurodegenerative diseases. In Parkinson's disease, progressive loss of dopaminergic neurons is accompanied by polymerization of the cytoplasmic protein
-synuclein (
S) into filamentous inclusions found in neuronal somata (Lewy bodies) and dendrites (Lewy neurites). Similar
S aggregates occur in cortical neurons in dementia with Lewy bodies. Numerous reports now indicate that
S can interact with lipids. We previously found that treating dopaminergic cells expressing
S with polyunsaturated fatty acids (PUFAs) induced the formation of soluble, sodium dodecyl sulfate-stable oligomers whereas treatment with saturated fatty acids did not. Here, we examine the relevance of
S-PUFA interactions to the development of Parkinson's disease-like cytopathology. Exposure of
S-overexpressing dopaminergic or neuronal cell lines to physiological levels of a PUFA induced the formation of proteinaceous inclusions in the cytoplasm. Kinetic experiments in-dicated that PUFA-induced soluble oligomers of
S precede these Lewy-like inclusions. Importantly, we found that
S oligomers were associated with cyto-toxicity, whereas the development of Lewy-like inclusions appeared to be protective. We conclude that alterations in PUFA levels can lead to aggregation of
S and subsequent deposition into potentially cyto-toxic oligomers that precede inclusions in dopa-minergic cells.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |